Search results

pomalidomide (Imnovid)

in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

pomalidomide (Imnovid)

In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.

isatuximab (Sarclisa)

In combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on the last therapy.

elotuzumab (Empliciti)

In combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.

daratumumab (Darzalex®)

In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy.

belantamab mafodotin (Blenrep)

In combination with pomalidomide and dexamethasone (BPd) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy including lenalidomide.

selinexor (Nexpovio)

In combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

December 2014 decisions news release

This month the Scottish Medicines Consortium (SMC) has accepted five new medicines. Among the decisions announced today are three cancer medicines and one medicine for a very rare condition.

April 2021 decisions news release

Advice on four new medicines for use in conditions including multiple myeloma and severe migraine has today (Monday 12 April) been published by the Scottish Medicines Consortium. A new medicine for Duchenne Muscular Dystrophy has now also been included in the ultra-orphan pathway.